GNNSF (Genscript Biotech) Total Liabilities: $888.6 Mil (As of Dec. 2025)

What is Genscript Biotech Total Liabilities?

Genscript Biotech GNNSF 66 Total Liabilities is $888.6 Mil as of Dec. 2025. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.50 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Genscript Biotech's Total Liabilities for the quarter that ended in Dec. 2025 was $888.6 Mil.

Genscript Biotech's quarterly Total Liabilities increased from Dec. 2024 ($954.91 Mil) to Jun. 2025 ($1,013.29 Mil) but then declined from Jun. 2025 ($1,013.29 Mil) to Dec. 2025 ($888.59 Mil).

Genscript Biotech's annual Total Liabilities declined from Dec. 2023 ($1,342.95 Mil) to Dec. 2024 ($954.91 Mil) and declined from Dec. 2024 ($954.91 Mil) to Dec. 2025 ($888.59 Mil).

Genscript Biotech Total Liabilities Related Terms

Genscript Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Genscript Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genscript Biotech Total Liabilities Chart

Genscript Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

846.18

1,183.72

1,342.95

954.91

888.59

Genscript Biotech Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Total Liabilities	Get a 7-Day Free Trial															1,342.95	1,507.66	954.91	1,013.29	888.59

66GF Score

Genscript Biotech Corp GNNSF

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Genscript Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genscript Biotech's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	720.17	+	(55.007	+	99.941
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	13.469)
	=	888.6

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	4853.277	-	3964.69
	=	888.6

Genscript Biotech's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	720.17	+	(55.007	+	99.941
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	13.469)
	=	888.6

Total Liabilities	=	Total Assets (Q: Dec. 2025 )	-	Total Equity (Q: Dec. 2025 )
	=	4853.277	-	3964.69
	=	888.6

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $888.6 Mil mean?

Genscript Biotech (GNNSF) has a Total Liabilities of $888.6 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genscript Biotech and its competitors.

Is Genscript Biotech's Total Liabilities too high?

Genscript Biotech's current Total Liabilities is $888.6 Mil. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Genscript Biotech's Total Liabilities compare to VRTX and REGN?

Genscript Biotech's Total Liabilities of $888.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genscript Biotech and its competitors. Genscript Biotech's current Total Liabilities is $888.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Genscript Biotech stock overvalued right now?

Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.50, compared to a current price of $1.60 — trading 36% below its estimated fair value. The current Total Liabilities is $888.6 Mil. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Total Liabilities is $888.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genscript Biotech (GNNSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued. The current stock price of $1.60 is trading 36% below its estimated GF Value™ of $2.50. GuruFocus considers Genscript Biotech to be Significantly Undervalued.

Key valuation signals for GNNSF:

Total Liabilities: $888.6 Mil
GF Value™: $2.50 vs. price of $1.60 (36% below fair value)
GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genscript Biotech Business Description

Industry Healthcare Biotechnology

Comparable Companies HKSE:09969 HKSE:02162 HKSE:01877 HKSE:02696 HKSE:09606 HKSE:07666 HKSE:06872 HKSE:06855 HKSE:02335 HKSE:01779 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 01548:Hong Kong G51:Germany

Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854

Website https://www.genscript.com

GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.

66GF Score

Get the complete analysis for GNNSF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60

Price

$2.50

GF Value

View GNNSF Analysis

See Total Liabilities data for all stocks →